BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33767315)

  • 1. Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma.
    Zhu Y; Mao Y; Chen J; Qiu Y; Guan Y; Wang Z; He J
    Sci Rep; 2021 Mar; 11(1):6933. PubMed ID: 33767315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.
    Zhu Y; Chen J; Kong W; Mao L; Kong W; Zhou Q; Zhou Z; Zhu B; Wang Z; He J; Qiu Y
    Eur Radiol; 2018 Jan; 28(1):159-169. PubMed ID: 28752218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
    Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
    Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative Computed Tomography Features of Intrahepatic Cholangiocarcinoma for Predicting Lymph Node Metastasis and Overall Survival.
    Zhu Y; Mao Y; Chen J; Qiu Y; Wang Z; He J
    J Comput Assist Tomogr; 2019; 43(5):729-735. PubMed ID: 31490892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation.
    Mosconi C; Cucchetti A; Bruno A; Cappelli A; Bargellini I; De Benedittis C; Lorenzoni G; Gramenzi A; Tarantino FP; Parini L; Pettinato V; Modestino F; Peta G; Cioni R; Golfieri R
    Eur Radiol; 2020 Aug; 30(8):4534-4544. PubMed ID: 32227266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.
    Wang T; Drill E; Vakiani E; Pak LM; Boerner T; Askan G; Schvartzman JM; Simpson AL; Jarnagin WR; Sigel CS
    Hum Pathol; 2019 Sep; 91():19-25. PubMed ID: 31121195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of small intrahepatic mass-forming cholangiocarcinoma from small liver abscess by dual source dual-energy CT quantitative parameters.
    Kim JE; Kim HO; Bae K; Cho JM; Choi HC; Choi DS
    Eur J Radiol; 2017 Jul; 92():145-152. PubMed ID: 28624012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A radiomic-based model of different contrast-enhanced CT phase for differentiate intrahepatic cholangiocarcinoma from inflammatory mass with hepatolithiasis.
    Xue B; Wu S; Zhang M; Hong J; Liu B; Xu N; Zeng Q; Tang K; Zheng X
    Abdom Radiol (NY); 2021 Aug; 46(8):3835-3844. PubMed ID: 33728532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
    Xiang X; Liu Z; Zhang C; Li Z; Gao J; Zhang C; Cao Q; Cheng J; Liu H; Chen D; Cheng Q; Zhang N; Xue R; Bai F; Zhu J
    Adv Sci (Weinh); 2021 Sep; 8(17):e2101230. PubMed ID: 34250753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: based on the multivariate analysis of contrast-enhanced computed tomography findings.
    Zhao YJ; Chen WX; Wu DS; Zhang WY; Zheng LR
    Abdom Radiol (NY); 2016 May; 41(5):978-89. PubMed ID: 27193795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
    Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
    JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study.
    Bisdas S; Shen H; Thust S; Katsaros V; Stranjalis G; Boskos C; Brandner S; Zhang J
    Sci Rep; 2018 Apr; 8(1):6108. PubMed ID: 29666413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrahepatic peripheral cholangiocarcinoma: CT evaluation.
    Valls C; Gumà A; Puig I; Sanchez A; Andía E; Serrano T; Figueras J
    Abdom Imaging; 2000; 25(5):490-6. PubMed ID: 10931983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
    Zhang X; Tian Q; Wang L; Liu Y; Li B; Liang Z; Gao P; Zheng K; Zhao B; Lu H
    J Magn Reson Imaging; 2018 Oct; 48(4):916-926. PubMed ID: 29394005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Tsunematsu S; Chuma M; Kamiyama T; Miyamoto N; Yabusaki S; Hatanaka K; Mitsuhashi T; Kamachi H; Yokoo H; Kakisaka T; Tsuruga Y; Orimo T; Wakayama K; Ito J; Sato F; Terashita K; Nakai M; Tsukuda Y; Sho T; Suda G; Morikawa K; Natsuizaka M; Nakanishi M; Ogawa K; Taketomi A; Matsuno Y; Sakamoto N
    Abdom Imaging; 2015 Aug; 40(6):1492-9. PubMed ID: 25579172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clear Cell Renal Cell Carcinoma: Machine Learning-Based Quantitative Computed Tomography Texture Analysis for Prediction of Fuhrman Nuclear Grade.
    Bektas CT; Kocak B; Yardimci AH; Turkcanoglu MH; Yucetas U; Koca SB; Erdim C; Kilickesmez O
    Eur Radiol; 2019 Mar; 29(3):1153-1163. PubMed ID: 30167812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.
    Li F; Li Q; Liu Y; Han J; Zheng W; Huang Y; Zheng X; Cao L; Zhou JH
    Eur Radiol; 2020 Jan; 30(1):461-470. PubMed ID: 31297632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
    Farshidfar F; Zheng S; Gingras MC; Newton Y; Shih J; Robertson AG; Hinoue T; Hoadley KA; Gibb EA; Roszik J; Covington KR; Wu CC; Shinbrot E; Stransky N; Hegde A; Yang JD; Reznik E; Sadeghi S; Pedamallu CS; Ojesina AI; Hess JM; Auman JT; Rhie SK; Bowlby R; Borad MJ; ; Zhu AX; Stuart JM; Sander C; Akbani R; Cherniack AD; Deshpande V; Mounajjed T; Foo WC; Torbenson MS; Kleiner DE; Laird PW; Wheeler DA; McRee AJ; Bathe OF; Andersen JB; Bardeesy N; Roberts LR; Kwong LN
    Cell Rep; 2017 Mar; 18(11):2780-2794. PubMed ID: 28297679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.